Fall in plasma ghrelin concentrations after cisplatin-based chemotherapy in esophageal cancer patients

Yuichiro Hiura, Shuji Takiguchi, Kazuyoshi Yamamoto, Yukinori Kurokawa, Makoto Yamasaki, Kiyokazu Nakajima, Hiroshi Miyata, Yoshiyuki Fujiwara, Masaki Mori, Yuichiro Doki

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Background Chemotherapeutic agents, especially cisplatin, cause severe gastrointestinal disorders, including nausea, vomiting, and anorexia,which markedly impair quality of life and encourage discontinuation of chemotherapy. Since cisplatin was recently reported to decrease plasma ghrelin and food intake in rodents, we monitored the plasma ghrelin level and its association with nutritional status and adverse events during chemotherapy in patients with esophageal cancer. Patients and methods Twenty patients with advanced esophageal cancer who underwent cisplatin-based neoadjuvant chemotherapy were enrolled in a prospective observational study. Changes in gastrointestinal hormones including ghrelin were measured and correlated with feeding activity, including appetite and dietary intake, nutritional status including rapid turnover proteins, and adverse events from chemotherapy. Results Plasma total ghrelin significantly decreased at days 3 and 8 of chemotherapy but recovered at day 28 (baseline: 140 ± 54; day 3: 107 ± 46; day 8: 82 ± 32; day 28: 126 ± 43 fmol/ml; p = 0.023 for day 3 and p = 0.034 for day 8). No changes were noted in plasma leptin (baseline: 3.2 ± 1.8; day 8: 2.5 ± 1.5 ng/ml; p = 0.18). Among blood nutritional parameters, transferrin was the only parameter that decreased significantly and its decline, as well as loss of oral intake and appetite, correlated significantly with plasma ghrelin levels (p = 0.0013, p = 0.0063, and p = 0.013, respectively). Neutropenia and anorexia were more frequent in patients with low plasma ghrelin than in those with high plasma ghrelin (p = 0.015 and p = 0.011, respectively). Conclusion Cisplatin-based chemotherapy significantly reduced plasma ghrelin and feeding activity. Ghrelin is a potentially useful novel therapy for minimizing the adverse effects of chemotherapy.

Original languageEnglish
Pages (from-to)316-323
Number of pages8
JournalInternational Journal of Clinical Oncology
Volume17
Issue number4
DOIs
Publication statusPublished - Aug 1 2012
Externally publishedYes

Fingerprint

Ghrelin
Esophageal Neoplasms
Cisplatin
Drug Therapy
Anorexia
Appetite
Nutritional Status
Gastrointestinal Hormones
Transferrin
Leptin
Neutropenia
Nausea
Vomiting
Observational Studies
Rodentia
Eating
Quality of Life
Prospective Studies

All Science Journal Classification (ASJC) codes

  • Surgery
  • Hematology
  • Oncology

Cite this

Fall in plasma ghrelin concentrations after cisplatin-based chemotherapy in esophageal cancer patients. / Hiura, Yuichiro; Takiguchi, Shuji; Yamamoto, Kazuyoshi; Kurokawa, Yukinori; Yamasaki, Makoto; Nakajima, Kiyokazu; Miyata, Hiroshi; Fujiwara, Yoshiyuki; Mori, Masaki; Doki, Yuichiro.

In: International Journal of Clinical Oncology, Vol. 17, No. 4, 01.08.2012, p. 316-323.

Research output: Contribution to journalArticle

Hiura, Y, Takiguchi, S, Yamamoto, K, Kurokawa, Y, Yamasaki, M, Nakajima, K, Miyata, H, Fujiwara, Y, Mori, M & Doki, Y 2012, 'Fall in plasma ghrelin concentrations after cisplatin-based chemotherapy in esophageal cancer patients', International Journal of Clinical Oncology, vol. 17, no. 4, pp. 316-323. https://doi.org/10.1007/s10147-011-0289-0
Hiura, Yuichiro ; Takiguchi, Shuji ; Yamamoto, Kazuyoshi ; Kurokawa, Yukinori ; Yamasaki, Makoto ; Nakajima, Kiyokazu ; Miyata, Hiroshi ; Fujiwara, Yoshiyuki ; Mori, Masaki ; Doki, Yuichiro. / Fall in plasma ghrelin concentrations after cisplatin-based chemotherapy in esophageal cancer patients. In: International Journal of Clinical Oncology. 2012 ; Vol. 17, No. 4. pp. 316-323.
@article{df9198ff6b1f4ff0af000941d58a5dad,
title = "Fall in plasma ghrelin concentrations after cisplatin-based chemotherapy in esophageal cancer patients",
abstract = "Background Chemotherapeutic agents, especially cisplatin, cause severe gastrointestinal disorders, including nausea, vomiting, and anorexia,which markedly impair quality of life and encourage discontinuation of chemotherapy. Since cisplatin was recently reported to decrease plasma ghrelin and food intake in rodents, we monitored the plasma ghrelin level and its association with nutritional status and adverse events during chemotherapy in patients with esophageal cancer. Patients and methods Twenty patients with advanced esophageal cancer who underwent cisplatin-based neoadjuvant chemotherapy were enrolled in a prospective observational study. Changes in gastrointestinal hormones including ghrelin were measured and correlated with feeding activity, including appetite and dietary intake, nutritional status including rapid turnover proteins, and adverse events from chemotherapy. Results Plasma total ghrelin significantly decreased at days 3 and 8 of chemotherapy but recovered at day 28 (baseline: 140 ± 54; day 3: 107 ± 46; day 8: 82 ± 32; day 28: 126 ± 43 fmol/ml; p = 0.023 for day 3 and p = 0.034 for day 8). No changes were noted in plasma leptin (baseline: 3.2 ± 1.8; day 8: 2.5 ± 1.5 ng/ml; p = 0.18). Among blood nutritional parameters, transferrin was the only parameter that decreased significantly and its decline, as well as loss of oral intake and appetite, correlated significantly with plasma ghrelin levels (p = 0.0013, p = 0.0063, and p = 0.013, respectively). Neutropenia and anorexia were more frequent in patients with low plasma ghrelin than in those with high plasma ghrelin (p = 0.015 and p = 0.011, respectively). Conclusion Cisplatin-based chemotherapy significantly reduced plasma ghrelin and feeding activity. Ghrelin is a potentially useful novel therapy for minimizing the adverse effects of chemotherapy.",
author = "Yuichiro Hiura and Shuji Takiguchi and Kazuyoshi Yamamoto and Yukinori Kurokawa and Makoto Yamasaki and Kiyokazu Nakajima and Hiroshi Miyata and Yoshiyuki Fujiwara and Masaki Mori and Yuichiro Doki",
year = "2012",
month = "8",
day = "1",
doi = "10.1007/s10147-011-0289-0",
language = "English",
volume = "17",
pages = "316--323",
journal = "International Journal of Clinical Oncology",
issn = "1341-9625",
publisher = "Springer Japan",
number = "4",

}

TY - JOUR

T1 - Fall in plasma ghrelin concentrations after cisplatin-based chemotherapy in esophageal cancer patients

AU - Hiura, Yuichiro

AU - Takiguchi, Shuji

AU - Yamamoto, Kazuyoshi

AU - Kurokawa, Yukinori

AU - Yamasaki, Makoto

AU - Nakajima, Kiyokazu

AU - Miyata, Hiroshi

AU - Fujiwara, Yoshiyuki

AU - Mori, Masaki

AU - Doki, Yuichiro

PY - 2012/8/1

Y1 - 2012/8/1

N2 - Background Chemotherapeutic agents, especially cisplatin, cause severe gastrointestinal disorders, including nausea, vomiting, and anorexia,which markedly impair quality of life and encourage discontinuation of chemotherapy. Since cisplatin was recently reported to decrease plasma ghrelin and food intake in rodents, we monitored the plasma ghrelin level and its association with nutritional status and adverse events during chemotherapy in patients with esophageal cancer. Patients and methods Twenty patients with advanced esophageal cancer who underwent cisplatin-based neoadjuvant chemotherapy were enrolled in a prospective observational study. Changes in gastrointestinal hormones including ghrelin were measured and correlated with feeding activity, including appetite and dietary intake, nutritional status including rapid turnover proteins, and adverse events from chemotherapy. Results Plasma total ghrelin significantly decreased at days 3 and 8 of chemotherapy but recovered at day 28 (baseline: 140 ± 54; day 3: 107 ± 46; day 8: 82 ± 32; day 28: 126 ± 43 fmol/ml; p = 0.023 for day 3 and p = 0.034 for day 8). No changes were noted in plasma leptin (baseline: 3.2 ± 1.8; day 8: 2.5 ± 1.5 ng/ml; p = 0.18). Among blood nutritional parameters, transferrin was the only parameter that decreased significantly and its decline, as well as loss of oral intake and appetite, correlated significantly with plasma ghrelin levels (p = 0.0013, p = 0.0063, and p = 0.013, respectively). Neutropenia and anorexia were more frequent in patients with low plasma ghrelin than in those with high plasma ghrelin (p = 0.015 and p = 0.011, respectively). Conclusion Cisplatin-based chemotherapy significantly reduced plasma ghrelin and feeding activity. Ghrelin is a potentially useful novel therapy for minimizing the adverse effects of chemotherapy.

AB - Background Chemotherapeutic agents, especially cisplatin, cause severe gastrointestinal disorders, including nausea, vomiting, and anorexia,which markedly impair quality of life and encourage discontinuation of chemotherapy. Since cisplatin was recently reported to decrease plasma ghrelin and food intake in rodents, we monitored the plasma ghrelin level and its association with nutritional status and adverse events during chemotherapy in patients with esophageal cancer. Patients and methods Twenty patients with advanced esophageal cancer who underwent cisplatin-based neoadjuvant chemotherapy were enrolled in a prospective observational study. Changes in gastrointestinal hormones including ghrelin were measured and correlated with feeding activity, including appetite and dietary intake, nutritional status including rapid turnover proteins, and adverse events from chemotherapy. Results Plasma total ghrelin significantly decreased at days 3 and 8 of chemotherapy but recovered at day 28 (baseline: 140 ± 54; day 3: 107 ± 46; day 8: 82 ± 32; day 28: 126 ± 43 fmol/ml; p = 0.023 for day 3 and p = 0.034 for day 8). No changes were noted in plasma leptin (baseline: 3.2 ± 1.8; day 8: 2.5 ± 1.5 ng/ml; p = 0.18). Among blood nutritional parameters, transferrin was the only parameter that decreased significantly and its decline, as well as loss of oral intake and appetite, correlated significantly with plasma ghrelin levels (p = 0.0013, p = 0.0063, and p = 0.013, respectively). Neutropenia and anorexia were more frequent in patients with low plasma ghrelin than in those with high plasma ghrelin (p = 0.015 and p = 0.011, respectively). Conclusion Cisplatin-based chemotherapy significantly reduced plasma ghrelin and feeding activity. Ghrelin is a potentially useful novel therapy for minimizing the adverse effects of chemotherapy.

UR - http://www.scopus.com/inward/record.url?scp=84867286561&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84867286561&partnerID=8YFLogxK

U2 - 10.1007/s10147-011-0289-0

DO - 10.1007/s10147-011-0289-0

M3 - Article

VL - 17

SP - 316

EP - 323

JO - International Journal of Clinical Oncology

JF - International Journal of Clinical Oncology

SN - 1341-9625

IS - 4

ER -